LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an ...

Earnings Estimate Revisions for Shionogi & Co. This company is expected to earn $0.27 per share for the fiscal year ending March 2025, which represents a year-over-year change of -58.5%.

However, this allows Shionogi to be the next great COVID opportunity, offering both significant profit generation for shareholder benefit and undervaluation. So far, Xocova has already allowed for ...

Shionogi & Co.’s experimental Covid-19 treatment Xocova failed to win the backing of health experts in Japan who said there wasn’t enough data to show the medicine’s efficacy. The panel ...

Shionogi has been awarded $375m by the US Department of Health and Human Services (HHS) to develop a long-acting therapeutic aimed at protecting vulnerable populations from Covid-19. The funding ...

Japan has approved the Shionogi's antiviral therapy, Xocova, for COVID-19 on an emergency basis. The government has also purchased 1 million doses initially, estimated to be worth $2.5 billion USD.

The win goes to local drugmaker Shionogi, which has clinched an emergency approval for its oral antiviral Xocova from Japan’s Ministry of Health, Labour and Welfare (MHLW) to treat SARS-CoV-2 ...

TOKYO, Feb 27 (Reuters) - Japan's Shionogi & Co Ltd (4507.T), opens new tab believes its COVID-19 pill will easily garner $2 billion in annual sales if it secures U.S. approval, which the company ...

Shionogi & Co. shares fell sharply Thursday morning after a Japanese government panel rejected granting emergency approval for the company’s Covid-19 drug. The company’s shares were recently 8 ...

There are a lot of activities happening. There are hundreds of booths, in multiple different therapeutic categories,” says Brian Conway, associate director, marketing at Shionogi. The Japanese ...

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional ...